drugset

drugset / Trial / NCT07251998

Efficacy and Safety of ICP-332 Versus Placebo in Participants With Moderate to Severe Plaque Psoriasis

NCT07251998 ↗

Phase 2 Recruiting 172 enrolled Beijing InnoCare Pharma Tech Co., Ltd.

RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to compare the efficacy and safety of ICP-332 to placebo in participants with moderate-to-severe plaque psoriasis.

Timeline

Start: 2025-12-22
Primary completion: 2026-10
Completion: 2027-05

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	ICP-332	Unknown	—	—

Indications